{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Signs+and+Symptoms%2C+Respiratory&page=20",
    "query": {
      "condition": "Signs and Symptoms, Respiratory",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 4706,
    "total_pages": 471,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Signs+and+Symptoms%2C+Respiratory&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Signs+and+Symptoms%2C+Respiratory&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T11:03:27.978Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00445965",
      "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Intraocular Melanoma",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Metastatic Cancer",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Retinoblastoma",
        "Sarcoma",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "iodine I 131 monoclonal antibody 3F8",
          "type": "RADIATION"
        },
        {
          "name": "131I-3F8",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 78,
      "start_date": "2006-01",
      "completion_date": "2023-02-01",
      "has_results": true,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-10-16T11:03:27.978Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445965"
    },
    {
      "nct_id": "NCT00393367",
      "title": "Budesonide Inhalation Suspension for Acute Asthma in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma",
        "Acute Asthma",
        "Reactive Airway Exacerbation"
      ],
      "interventions": [
        {
          "name": "Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone, prednisone, or methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Albuterol, ipratropium bromide",
          "type": "DRUG"
        },
        {
          "name": "Ipratropium bromide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 179,
      "start_date": "2006-12",
      "completion_date": "2007-11",
      "has_results": true,
      "last_update_posted_date": "2012-08-10",
      "last_synced_at": "2026-10-16T11:03:27.978Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00393367"
    },
    {
      "nct_id": "NCT06684119",
      "title": "Pediatric Positive End Expiratory Pressure (PEEP) Titration Using Electrical Impedence Tomography (EIT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pediatric Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "Electrical Impedance Tomography positive end-expiratory pressure titration",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-12-10",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-10-16T11:03:27.978Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06684119"
    },
    {
      "nct_id": "NCT02185092",
      "title": "Probiotic Use in Patients With Prior COPD Exacerbation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COPD",
        "Obstructive Lung Disease"
      ],
      "interventions": [
        {
          "name": "Lactobacillus GG",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Sugar pill",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-10",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-05-23",
      "last_synced_at": "2026-10-16T11:03:27.978Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02185092"
    },
    {
      "nct_id": "NCT01624792",
      "title": "Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Muscle Wasting"
      ],
      "interventions": [
        {
          "name": "Olive oil",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Fish oil",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Fish oil and placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Texas A&M University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2011-10-25",
      "completion_date": "2016-06-29",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-10-16T11:03:27.978Z",
      "location_count": 1,
      "location_summary": "College Station, Texas",
      "locations": [
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624792"
    },
    {
      "nct_id": "NCT00157092",
      "title": "Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alpha1-antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Aerosolized, Recombinant Alpha 1-Antitrypsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2004-03-01",
      "completion_date": "2004-10-14",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-10-16T11:03:27.978Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00157092"
    },
    {
      "nct_id": "NCT00730119",
      "title": "Evaluation Of The GE Monitor Product Line",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-invasive Blood Pressure",
        "Temperature",
        "SpO2",
        "Respiration",
        "ECG"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Minute and older"
      },
      "enrollment_count": 0,
      "start_date": "2001-10",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2017-08-08",
      "last_synced_at": "2026-10-16T11:03:27.978Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730119"
    },
    {
      "nct_id": "NCT02393807",
      "title": "The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF 06260414 solid dose formulation",
          "type": "DRUG"
        },
        {
          "name": "PF-06260414 nanosuspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-06",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-10-16T11:03:27.978Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02393807"
    },
    {
      "nct_id": "NCT06142019",
      "title": "Pulse Oximeter Accuracy in Healthy Humans During Hypoxia",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypoxia",
        "Skin Pigmentation"
      ],
      "interventions": [
        {
          "name": "Controlled desaturation (hypoxemia)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 10000,
      "start_date": "2021-11-29",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-16T11:03:27.978Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06142019"
    },
    {
      "nct_id": "NCT01966107",
      "title": "Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD",
        "Chronic Obstructive Pulmonary Disease",
        "Moderate to Very Severe COPD"
      ],
      "interventions": [
        {
          "name": "Aclidinium Bromide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "40 Years to 130 Years"
      },
      "enrollment_count": 3635,
      "start_date": "2013-10-16",
      "completion_date": "2017-09-21",
      "has_results": true,
      "last_update_posted_date": "2018-12-06",
      "last_synced_at": "2026-10-16T11:03:27.978Z",
      "location_count": 433,
      "location_summary": "Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01966107"
    }
  ]
}